Key facts
- This page summarizes Celadon Partners SPV 24's Form 4 filing for Senti Biosciences, Inc. (SNTI).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Mar 2025, 11:52.
Celadon Partners SPV 24 - 10 Mar 2025 Form 4 Insider Report for Senti Biosciences, Inc. (SNTI)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- SNTI
- Reported as of
- 10 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Mar 2025, 11:52:40 UTC
- Prior SEC filing
- 13 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- Celadon Partners SPV 24, By: Celadon Partners, LLC (as sole manager of Celadon Partners SPV 24), /s/ David Egglishaw, as manager of Celadon Partners, LLC
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Celadon Partners SPV 24 filed Form 4 for Senti Biosciences, Inc. (SNTI) on 14 Mar 2025.
Change
- Previous filing in this sequence was filed on 13 Mar 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SNTI
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +9,777,000
- Change %
- Price
- Shares after
- 9,777,000
- Date
- 10 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SNTI
transaction
Derivative
Series A Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -9,777
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 10 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,777,000
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Each share of Series A Convertible Preferred Stock (the "Series A Preferred Stock") was convertible into 1,000 shares of Common Stock either (i) automatically, at the Issuer's option or (ii) upon the election of the holder. On March 10, 2025, the Issuer exercised its right to automatically convert each share of Series A Preferred Stock, resulting in the acquisition of 9,777,000 shares of Common Stock. The Series A Preferred Stock had no expiration date.